SP-1000 / Samaritan Pharma - LARVOL DELTA

Application of domestic jingfeng single-port robotic-assisted surgery in multisite diseases of oropharyngeal-head and neck region: case series (PubMed, Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi) - "A retrospective analysis was conducted on the clinical data of 6 patients who underwent Jingfeng SP1000 single-port robotic-assisted surgery at our hospital from June 2025 to July 2025...This case series confirms the safety and feasibility of the domestic Jingfeng single-port robot in transoral and axillary approach surgeries in oropharyngeal-head and neck surgery. Its single-port design reduces trauma and the risk of robotic arm collision, adapts to minimally invasive needs, and its domestic production attribute lowers costs to facilitate popularization, providing a new option for such patients."

Journal • Retrospective data • Cervical Cancer • Hypopharyngeal Cancer • Obstructive Sleep Apnea • Oncology • Otorhinolaryngology • Respiratory Diseases • Sleep Disorder • Solid Tumor • Thyroid Gland Carcinoma

Single-Port Robotic Anatomical Lung Resection Using the Novel Chinese SP1000 Robotic System: Initial Experience (IASLC-WCLC 2025) - "Despite the subcostal approach's longer operative times and greater blood loss, it remains a viable option under specific surgical conditions. Future research should focus on optimizing these techniques to enhance their clinical efficacy."

Infectious Disease • Movement Disorders

Evaluation of the safety and effectiveness of the Jingfeng Single-Port Laparoscopic Surgery System (SP1000) compared to the Jingfeng Thoracoabdominal Laparoscopic Surgery System (MP1000) in a single-center, randomized, single-blind, parallel-controlled clinical study (ChiCTR) - P=N/A | N=50 | Not yet recruiting | Sponsor: The First Affiliated Hospital of Anhui Medical University; The First Affiliated Hospital of Anhui Medical University

New trial • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Single-Port Robotic Resection of Recurrent Hepatocellular Carcinoma in the Right Anterior Lobe: A Case Report. (PubMed, Int J Med Robot) - "The EDGE SP1000 has superior capabilities that enable precise manipulation within the confined space of the abdomen and allow minimally invasive single-port surgery with aesthetic benefits."

Journal • Hepatocellular Cancer • Liver Cancer • Oncology • Solid Tumor

Clinical trial to evaluate the safety and efficacy of the endoscopic surgical instrument control system (SP1000) in otolaryngology-head and neck surgery (ChiCTR) - P=N/A | N=33 | Recruiting | Sponsor: Zhejiang Provincial People's Hospital; Shenzhen Jingfeng Medical Technology Co., Ltd.

New trial • Endocrine Disorders • Laryngeal Cancer • Oncology • Otorhinolaryngology • Thyroid Gland Carcinoma

Initial Urological Surgery Using a New Domestic Single-Port Surgical Robotic System. (PubMed, J Endourol) - "The surgeon reported that the device was comfortable to use, with a NASA-TLX score of 35.67 ± 4.23. It is safe and feasible to perform urologic procedure using the EDGE single-port endoscopic surgical robot (EDGE SP1000) control system."

Journal • Cardiovascular • Urology

Transumbilical robotic single-port (RSP) sacrohysteropexy: A case report and literature review. (PubMed, Int J Gynaecol Obstet) - "After full communication and signing the informed consent, the patient received transumbilical single-port laparoscopic sacrohysteropexy with the assistance of a robot under general anesthesia on January 11, 2024. Our hospital successfully performed the single-port robot-assisted transumbilical laparoscopic sacrohysteropexy in China, which confirms the safety and effectiveness of Jingfeng single port surgical robot system SP1000 in clinical application."

Journal • Review • Anesthesia

Initial Outcomes and Methodologies of a Novel Single-Port Robotic Surgery in Gynecology. (PubMed, JSLS) - "The practicality and safety of the EDGE SP1000 system have been demonstrated in a subset of patients. However, more study and specific surgical skills are required to completely comprehend the benefits and long-term outcomes of robotic surgical systems."

Journal • Retrospective data • Gynecologic Cancers • Gynecology • Pain • Women's Health

Robotic-Assisted Single-Port Laparoscopic Sacrohysteropexy (AAGL 2024) - "Our hospital has successfully performed robot-assisted transumbilical single-port laparoscopic sacrohysteropexy, confirming the safety and effectiveness of the SP1000 precision single-port robotic system in clinical applications. Previously, robots were mainly used in tumor-related surgeries, and their application in pelvic floor dysfunction disorders is just beginning. There is limited data on the safety and effectiveness of robotic systems in this area, and further multicenter, large-sample prospective randomized controlled trials will be needed to confirm their safety and effectiveness in the future."

Anesthesia • Developmental Disorders • Oncology • Pain

COVID-19 SPIKE AND PARTICULATE MATTER CO-EXPOSURE: IN VITRO MODELING OF INFLAMMATION (CHEST 2024) - "SP exposure increases IL-6 expression in a dose dependent manner. At SP100 and SP1000, the cells may have reached an inflammatory ceiling, with IL-6 at or greater than that of the LPS cells. PM exposure trends towards increasing IL-6 in a dose dependent manner."

Preclinical • Acute Respiratory Distress Syndrome • Chronic Obstructive Pulmonary Disease • Dyslipidemia • Genetic Disorders • Infectious Disease • Inflammation • Metabolic Disorders • Novel Coronavirus Disease • Obesity • Pulmonary Disease • Respiratory Diseases • IL6

Single-port robotic surgery using the EDGE SP1000 surgical system in gynaecology: Initial experience of a single institution. (PubMed, Int J Med Robot) - "EDGE SP1000 SP robotic surgical system is technically feasible and safe in various gynaecological surgeries with good cosmetic effects."

Journal • Surgery • Gynecologic Cancers • Gynecology

First preclinical experience with the newly developed EDGE SP1000 single-port robotic surgical system-assisted transanal total mesorectal excision. (PubMed, Gastroenterol Rep (Oxf)) - No abstract available

Journal • Preclinical

Preclinical evaluation of the new EDGE SP 1000 single-port robotic surgical system in gynecology minimal access surgery. (PubMed, Surg Endosc) - "This preclinical study of a new single-port surgical system for gynecologic procedures demonstrated the safety and feasibility of the EDGE SP1000 system in porcine models. Further studies are required to assess its clinical utility in the future."

Journal • Preclinical • Gynecology • Infectious Disease • Pain

Evaluate the Safety and Effectiveness of the Endoscopic Surgical Instrument Control System (SP1000). (clinicaltrials.gov) - P=N/A; N=36; Not yet recruiting; Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Clinical • New trial • Genito-urinary Cancer • Oncology • Urology

Evaluation of two commercial kits on the automated ELITe InGenius PCR platform for molecular diagnosis of toxoplasmosis. (PubMed, J Mol Diagn) - "The SP1000 cartridges (Elitech), which allow DNA extraction from 1 mL of template, showed very interesting performances on amniotic fluids samples. Overall, the two kits had very good performances on the InGenius platform, which offers a turn-key solution suitable for the molecular diagnosis of toxoplasmosis."

Journal • Infectious Disease

Robot assisted nephrectomy using the newly developed EDGE SP1000 single-port robotic surgical system: a feasibility study in porcine model. (PubMed, J Endourol) - "Conclusions This study shows that the EDGE SP1000 single-port robotic surgical system is safe and feasible for the use of nephrectomy in gilts. Our further work will expand the application of the EDGE SP1000 system to other urological procedures and accumulate more preclinical data for further clinical trial."

Journal • Urology

[VIRTUAL] DETECTION AND SIGNIFICANCE OF GREEN INCLUSIONS IN NEUTROPHILS: A FINDING THAT CLINICIANS SHOULD CARE (ISLH 2020) - "Smears were stained with May Grünwald-Giemsa using the slide maker-stainer SP1000i and they were analysed using the CellaVision DM96... These data point out that laboratories should be proactively screening for these inclusions and clinical pathologists should be aware of their link to a possible acute liver injury. This finding in the PB smear review should be considered a critical one, being mandatory to report to clinicians."

Clinical • Hematological Disorders • Leukopenia • Pain • Septic Shock

Targeting BCL-XL By Protac DT2216 Effectively Eliminates Leukemia Cells in T-ALL Pre-Clinical Models (ASH 2019) - "Next, we studied the sensitivity of ALL cells to ABT-199, DT2216 and the combination, in comparison with dual BCL-2/BCL-XL inhibitor ABT-263...After documenting bone marrow (BM) engraftment by flow cytometry in BM aspirates on Day 14 post cell injection, mice were randomized to receive vehicle, chemotherapy (“VDL”, VCR 0.15mg/kg, Dexa 5mg/kg, L-ASP 1000U/kg, ip., qw), DT2216 (15mg/kg, ip., q4d) or their combination for 3 weeks...DT2216 alone and in particular when combined with chemotherapy reduced leukemia burden and prolonged survival in T-ALL PDX models. This study suggests targeting BCL-XL by DT2216 represents highly effective and safe adjunct therapeutic modality in T-ALL."

IO Biomarker • BCL2L1

Efficacy and toxicity of reduced vs. standard dose pegylated asparaginase in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia. (PubMed, Leuk Lymphoma) - "All 11 patients who received PEG-ASP 1000 IU/m and 9/11 patients who received 500 IU/m achieved an ASNase level ≥0.1 IU/mL. Patients receiving RED experienced fewer total grade 3/4 toxicities during induction compared to SD (p = .02) while still attaining therapeutic ASNase levels. RED permits safer ASNase use in adults with ALL and should be tested in a larger cohort prospectively."

Clinical • Journal

"We are using a Sysmex SP 1000 automated hematologic, May-Grunwald/ Giemsa Stainer." (@BertGrijsen)

Reduced vs. standard dose native E. coli-asparaginase therapy in childhood acute lymphoblastic leukemia: long-term results of the randomized trial Moscow-Berlin 2002. (PubMed, J Cancer Res Clin Oncol) - "Our findings suggest that weekly 5000 U/mE. coli-ASP IM during consolidation therapy are equally effective, more cost-efficient and less toxic than 10000 U/m for SR patients with childhood ALL."

Clinical • Journal